Xiangjun Zhou

Dr. Xiangjun Zhou


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
LCLijia Chen
Lijia Chen
MZMingjie Zhang
Mingjie Zhang
MCMiao Chi
Miao Chi
ZYZehua Ye
Zehua Ye
BLBojun Li
Bojun Li
XZXiangjun Zhou
Xiangjun Zhou
Background/Objectives: Cisplatin-induced acute kidney injury (AKI) is a major adverse complication restricting cisplatin-based chemotherapy. Ferroptosis contributes substantially to proximal tubular epithelial injury during AKI. This work aimed to explore the renoprotective effect of echinacoside (ECH) and its underlying molecular mechanism against cisplatin-provoked AKI. Methods: Eight-week-old male C57BL/6 cisplatin-AKI mice models and HK-2 tubular epithelial cells were used for in vivo and in vitro experiments. Public single-cell transcriptome data and 4D-DIA proteomics were applied to screen key ferroptosis-associated molecules. Functional validation, Western blotting, and molecular docking simulations were performed to characterize the regulatory axis of ECH. Results: ECH ameliorated renal dysfunction, inflammation, and tubular damage in cisplatin-induced AKI. Omics analyses nominated Bap1 as a critical ferroptosis-related differential protein. ECH restored the Slc7a11/GPX4 pathway to restrain lipid peroxidation and mitochondrial ferroptotic damage. Molecular docking predicted a potential interaction between ECH and Bap1. ECH downregulated Bap1 protein expression, and Bap1 overexpression largely abrogated ECH-mediated anti-ferroptosis and renoprotective effects. Conclusions: ECH mitigates cisplatin-triggered AKI, which is associated with Bap1 downregulation, Slc7a11/GPX4 axis restoration, and ferroptosis suppression. The ECH-Bap1-ferroptosis regulatory relationship offers a candidate therapeutic target and natural agent for the preventive treatment of cisplatin-related nephrotoxicity.